Literature DB >> 16556162

Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels.

Isabelle Morard1, Gilles Mentha, Laurent Spahr, Pietro Majno, Antoine Hadengue, Olivier Huber, Philippe Morel, Emiliano Giostra.   

Abstract

BACKGROUND: Renal dysfunction is common after liver transplantation (LT). The aim of our study was to assess the prevalence of renal dysfunction 5 yr after LT and to identify risk factors for the development of this complication. PATIENTS AND METHODS: A total of 134 adult patients underwent LT from 1987 to 1998 and 74.6% of them were alive 5 yr after. Pre-LT, 1 and 5 yr post-LT renal function were calculated by Cockroft and modification of diet in renal disease (MDRD) formula. Since 1987 glomerular filtration rate (GFR) has been measured by radiolabeled tracers clearance (RTC). Risk factors for GFR < 50 mL/min were analyzed using a multivariate logistic regression model.
RESULTS: Mean pre-LT GFR was 79 and 85 mL/min with Cockroft and MDRD respectively; 11% of the patients had a GFR <or= 50 mL/min. 5 yr after LT, mean GFR was 63, 61 and 70 mL/min with MDRD, Cockroft and RTC respectively, GFR decreased by 26%, and 25% of the patients had a GFR < 50 mL/min. Independent risk factors associated with impaired renal function were: trough levels of cyclosporin A (CyA) >or= 150 microg/L or tacrolimus (FK) >or= 10 microg/L at 1 yr and CyA >or= 100 microg/L or FK >or= 8 microg/L at 5 yr.
CONCLUSION: 5 yr after LT, patients have lost 26% of their initial GFR and 25% of them have a GFR < 50 mL/min. This complication is predicted by high levels of calcineurin inhibitors (CNI). Therefore CNI levels should be reduced as low as possible and use of alternative drugs should be considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16556162     DOI: 10.1111/j.1399-0012.2005.00447.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  10 in total

1.  Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.

Authors:  Zhen-Yong Shao; Lu-Nan Yan; Wen-Tao Wang; Bo Li; Tian-Fu Wen; Jia-Yin Yang; Ming-Qing Xu; Ji-Chun Zhao; Yong-Gang Wei
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil.

Authors:  Masami Minemura; Yoshiharu Tokimitsu; Kazuto Tajiri; Yasuhiro Nakayama; Kengo Kawai; Hiroshi Kudo; Katsuharu Hirano; Yoshinari Atarashi; Yutaka Yata; Satoshi Yasumura; Terumi Takahara; Toshiro Sugiyama
Journal:  World J Hepatol       Date:  2010-12-27

3.  Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience.

Authors:  Εvangelos Cholongitas; Ioannis Goulis; Eleni Theocharidou; Nikolaos Antoniadis; Ioannis Fouzas; Dimitrios Giakoustidis; George Imvrios; Olga Giouleme; Vasilios Papanikolaou; Evangelos Akriviadis; Themistoklis Vasiliadis
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

4.  Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant.

Authors:  Yuehong Li; Binbin Li; Wei Wang; Jiaxuan Lv
Journal:  Exp Ther Med       Date:  2018-01-31       Impact factor: 2.447

5.  Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.

Authors:  Jing-Cheng Hao; Wen-Tao Wang; Lu-Nan Yan; Bo Li; Tian-Fu Wen; Jia-Yin Yang; Ming-Qing Xu; Ji-Chun Zhao; Yong-Gang Wei
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

6.  An analysis of tacrolimus-related complications in the first 30 days after liver transplantation.

Authors:  Lucas Souto Nacif; André Ibrahim David; Rafael Soares Pinheiro; Marcio Augusto Diniz; Wellington Andraus; Ruy Jorge Cruz; Luiz A Carneiro D'Albuquerque
Journal:  Clinics (Sao Paulo)       Date:  2014-11       Impact factor: 2.365

7.  Everolimus with or without mycophenolate mofetil in a liver transplantation setting: a single-center experience.

Authors:  Εvangelos Cholongitas; Ioannis Goulis; Eleni Theocharidou; Nikolaos Antoniadis; Ioannis Fouzas; George Imvrios; Olga Giouleme; Aliki Angelaki; Themistoklis Vasiliadis; Vasilios Papanikolaou; Evangelos Akriviadis
Journal:  Ann Gastroenterol       Date:  2018-05-25

8.  Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report.

Authors:  Motoyuki Tanaka; Takao Setoguchi; Yasuhiro Ishidou; Yoshiya Arishima; Masataka Hirotsu; Yoshinobu Saitoh; Shunsuke Nakamura; Hironori Kakoi; Satoshi Nagano; Masahiro Yokouchi; Junichi Kamizono; Setsuro Komiya
Journal:  Diagn Pathol       Date:  2012-08-20       Impact factor: 2.644

9.  The relationship between preoperative creatinine clearance and outcomes for patients undergoing liver transplantation: a retrospective observational study.

Authors:  Urs Wenger; Thomas A Neff; Christian E Oberkofler; Manuel Zimmermann; Paul A Stehberger; Marcel Scherrer; Reto A Schuepbach; Silvia R Cottini; Peter Steiger; Markus Béchir
Journal:  BMC Nephrol       Date:  2013-02-14       Impact factor: 2.388

10.  Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study.

Authors:  Styrbjörn Friman; Giuseppe Tisone; Frederik Nevens; Frank Lehner; Walter Santaniello; Wolf O Bechstein; Sergey V Zhuvarel; Helena Isoniemi; Oleg O Rummo; Jürgen Klempnauer; Swapneel Anaokar; Martin Hurst; Gbenga Kazeem; Nasrullah Undre; Pavel Trunečka
Journal:  Transplant Direct       Date:  2021-07-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.